News about Clinical Trials

Diamyd Medical Advances Type I Diabetes Phase III Efficacy Readout by Nine Months

Diamyd Medical has aligned with the US FDA to accelerate the primary efficacy readout of its Phase 3 DIAGNODE-III trial in type 1 diabetes from 24 to 15 months, enabling results to be available nine months earlier than previously planned.

Clinical Trials | 30/12/2025 | By News Bureau |  156

KEYTRUDA Plus Padcev Improves Survival Outcomes in MIBC

KEYTRUDA plus Padcev significantly improved survival and pathologic complete response rates in cisplatin-eligible patients with muscle-invasive bladder cancer when used before and after surgery.

Clinical Trials | 18/12/2025 | By News Bureau |  180

US FDA Approves Phase III Trial of Cadonilimab Against Nivolumab in Gastric Cancer

The FDA’s clearance enables a global phase III study evaluating Cadonilimab, in combination with chemotherapy, as a first-line option for HER2-negative, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma, directly comparing its efficacy to standard chemotherapy with or without Nivolumab.

Clinical Trials | 12/12/2025 | By Akanki |  386

J&J Reports 74% One-Year Disease-Free Survival with INLEXZO in High-Risk NMIBC

Johnson & Johnson reported strong new data from Cohort 4 of the SunRISe-1 study, showing that INLEXZO (gemcitabine intravesical system) achieved a 74 percent one-year disease-free survival rate in patients with BCG-unresponsive, high-risk papillary-only NMIBC, with over 95 percent progression-free and more than 92 percent avoiding bladder removal.

Clinical Trials | 06/12/2025 | By Dineshwori |  153

ALS Association Announces USD 2M Support for Emerging ALS Treatments

The ALS Association has awarded $2 million through its Hoffman ALS Clinical Trial Awards Program to advance two early-stage therapeutic candidates, supporting efforts to accelerate the development of new treatments for the disease.

Clinical Trials | 06/12/2025 | By Dineshwori |  284

Immorta Bio Reports Tumour Reduction Across Multiple Cancer Models with SenoVax

Immorta Bio has reported promising pre-clinical results showing that its anti-aging vaccine, SenoVax, reduced tumours across multiple validated cancer models. Developed in collaboration with academic institutions, the platform aims to dismantle tumour defense mechanisms and offer a non-toxic, longevity-driven approach to cancer treatment.

Clinical Trials | 05/12/2025 | By Dineshwori |  639

Ascletis Advances First Oral Triple Agonist ASC37 to Clinical Development

Ascletis has selected ASC37—its first oral GLP-1R/GIPR/GCGR triple peptide agonist—for clinical development. Using the company’s POTENT technology, ASC37 showed markedly higher oral bioavailability and drug exposure than leading agents in non-human primate studies.

Clinical Trials | 01/12/2025 | By Dineshwori |  244

New Innovation Hub to Make Maharashtra a Global Pharma & Biotech Hub

The government of Maharashtra plans to establish a state-of-the-art Life Sciences Innovation and Incubation Centre aimed at boosting research and development in pharmaceuticals, biotechnology, medical devices, diagnostics and digital health.

Clinical Trials | 29/11/2025 | By Darshana |  262

Pin Therapeutics Administers First Dose of PIN-5018 in Adenoid Cystic Carcinoma Patient

Pin Therapeutics, a clinical-stage biotechnology company focused on targeted protein degradation, has begun dosing in a Phase 1 clinical trial evaluating its CK1α-selective degrader, PIN-5018. The first patient enrolled in the study has adenoid cystic carcinoma (ACC), a rare malignancy with limited treatment options.

Clinical Trials | 24/11/2025 | By Dineshwori |  323

US FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer

PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC).

Clinical Trials | 24/11/2025 | By Dineshwori |  174